# Myelodysplastic Syndromes FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myelodysplastic-syndromes

> 12 upcoming FDA catalysts in myelodysplastic Syndromes: OJJAARA (momelotinib, GSK) on Jul to Oct 2027 (topline data readout); OJJAARA (momelotinib, GSK) on July 2027 (primary completion); luspatercept (BMY) on Mar to Jun 2028 (topline data readout); luspatercept (BMY) on March 2028 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 1, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | completed | "NCT06045689 (A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045689)) |
| March 17, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Myelodysplastic Syndromes | completed | "NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05490446)) |
| Jul to Oct 2027 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | Myelodysplastic Syndromes | scheduled | "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847867)) |
| July 2027 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Myelodysplastic Syndromes | scheduled | "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847867)) |
| Mar to Jun 2028 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949684)) |
| March 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05949684 (ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949684)) |
| Jun to Sep 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07319845)) |
| June 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT07319845 (A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07319845)) |
| Jul to Oct 2028 | [Oral azacitidine topline data readout](https://sec-api.dev/pdufa/oral-azacitidine) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05469737)) |
| July 2028 | [Oral azacitidine primary completion](https://sec-api.dev/pdufa/oral-azacitidine) | BMY | Myelodysplastic Syndromes | scheduled | "NCT05469737 (A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05469737)) |
| Sep to Dec 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06499285)) |
| September 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes | scheduled | "NCT06499285 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06499285)) |
| September 2030 | [Evrenzo® (roxadustat) primary completion](https://sec-api.dev/pdufa/roxadustat) | KYNB | Myelodysplastic Syndromes | scheduled | "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722988)) |
| Sep to Dec 2030 | [Evrenzo® (roxadustat) topline data readout](https://sec-api.dev/pdufa/roxadustat) | KYNB | Myelodysplastic Syndromes | scheduled | "NCT07722988 (A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor Kyntra Bio." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722988)) |

## Drugs

- [Luspatercept](https://sec-api.dev/pdufa/luspatercept) (BMY)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine) (BMY)
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat) (KYNB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myelodysplastic-syndromes.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Myelodysplastic Syndromes FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myelodysplastic-syndromes

```bibtex
@misc{secapidev_indications_myelodysplastic_syndromes_20261116,
  title        = {Myelodysplastic Syndromes FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myelodysplastic-syndromes}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myelodysplastic_syndromes_20261116","title":"Myelodysplastic Syndromes FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myelodysplastic-syndromes","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
